Navigation Links
BioMarin Announces Third Quarter 2009 Financial Results
Date:10/28/2009

===== ======= ======= Three Months Nine Months Ended Ended September 30, September 30, ------------- ------------- 2008 2009 2008 2009 ---- ---- ---- ---- $430 $1,192 $1,019 $3,179 Cost of sales Research and development expense 2,501 3,408 6,118 8,488 Selling, general and administrative expense 4,468 4,321 10,674 14,064 ----- ----- ------ ------ Total stock-based compensation expense $7,399 $8,921 $17,811 $25,731 ====== ====== ======= =======
          Reconciliation of GAAP Net Income (Loss) to Non-GAAP Net Income
                       (In millions, except per share data)
                                   (Unaudited)

                            Three Months     Nine Months
                               Ended            Ended       Year Ended
                           September 30,    September 30,   December 31,
                           -------------    -------------   ------------
                     Notes: 2008    2009    2008    2009    2008     2009
                     ------ ----    ----    ----    ----    ----     ----
                                                                  (forecast)

    GAAP Net                                                     (8.0) to
     Income (Loss)          $0.8    $6.6    $6.3   $(5.2)  $30.8    $(4.0)
        Stock-based
         compensation
         expense             7.4     8.9    17.8    25.7    25.3     35.0
        Upfront
         license
    
'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. BioMarin to Present at the Oppenheimer Healthcare Conference
2. BioMarin Acquires Huxley Pharmaceuticals, Inc.
3. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
4. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
5. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
7. BioMarin Announces FDA Approval for Kuvan
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Rigel Announces Presentations at Two Investor Conferences
10. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
11. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... MENLO PARK, Calif. , Oct. 27, 2014 /PRNewswire/ ... isolation of blood flow and delivery of fluids to ... the RenovoRx Board of Directors has appointed Shaun ... additional Member of the RenovoRx Board of Directors. Bagai ... medical technology industry. Bagai joined RenovoRx in ...
(Date:10/27/2014)... Research and Markets has announced the ... report to their offering. H1N1 influenza (zoonotic) ... of the swine H1N1 virus, known as H1N1v virus. The ... and lungs. H1N1 virus is an RNA virus belonging to ... such as humans, swine, birds, seals, and horses. Influenza A ...
(Date:10/27/2014)... CHICAGO , Oct. 27, 2014  Demonstrations ... and devices are being featured this week in ... 2014 Scientific Assembly where more than 7,000 emergency ... medicine and participating in educational courses. ... back drop of true-to-life emergency department environments, including ...
Breaking Medicine Technology:RenovoRx Board Names Shaun R. Bagai as CEO 2Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 2Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 3Emergency Medicine of the Future Demonstrated at ACEP14 2Emergency Medicine of the Future Demonstrated at ACEP14 3Emergency Medicine of the Future Demonstrated at ACEP14 4Emergency Medicine of the Future Demonstrated at ACEP14 5Emergency Medicine of the Future Demonstrated at ACEP14 6Emergency Medicine of the Future Demonstrated at ACEP14 7Emergency Medicine of the Future Demonstrated at ACEP14 8Emergency Medicine of the Future Demonstrated at ACEP14 9Emergency Medicine of the Future Demonstrated at ACEP14 10Emergency Medicine of the Future Demonstrated at ACEP14 11Emergency Medicine of the Future Demonstrated at ACEP14 12Emergency Medicine of the Future Demonstrated at ACEP14 13Emergency Medicine of the Future Demonstrated at ACEP14 14Emergency Medicine of the Future Demonstrated at ACEP14 15
... study presented at the American Association of Physicists in Medicine ... showed that 18FDG dose for Positron Emission Mammography (PEM) may ... quality. PEM scanners are high-resolution breast PET systems ... of a lesion.  The metabolic view assists physicians to make ...
... Aug. 23 Encorium Group, Inc. (Nasdaq: ENCO ... studies in over 30 countries for many of the world,s ... to commence a rights offering for up to 3,401,151 shares ... offering, each stockholder of record as of August 11, 2010 ...
Cached Medicine Technology:Preliminary Research Results Suggest up to 70% Reduction in Dose for Positron Emission Mammography Imaging 2Preliminary Research Results Suggest up to 70% Reduction in Dose for Positron Emission Mammography Imaging 3Encorium Group, Inc. Announces Terms of Proposed Rights Offering 2Encorium Group, Inc. Announces Terms of Proposed Rights Offering 3Encorium Group, Inc. Announces Terms of Proposed Rights Offering 4
(Date:10/30/2014)... Five months after their expansion, the AV ... branding and a website to accompany their recent change ... promotion to name partner earlier this year, Hodgkinson Street ... name and better reflect their combined litigation expertise. As ... to implement new branding reflects Hodgkinson Street Mepham’s collaborative ...
(Date:10/30/2014)... 2014 Radio listeners who indicate use ... the impact of traditional radio commercials and have overwhelmingly ... to influence a purchasing decision. , Those are some ... conducted by radio marketing company CRN International. The research ... results of respondents who indicated they have purchased or ...
(Date:10/30/2014)... Dennis Thompson HealthDay ... The Ebola outbreak in Liberia -- one of three West ... World Health Organization officials said Wednesday. Dr. Bruce Aylward, ... the number of burials in Liberia and no increase in ... global push to tame the epidemic may be making some ...
(Date:10/30/2014)... Horse Sense & Sensitivity ... special needs individuals in the Jacksonville area, will be ... from 10-2:00 p.m. at Bailey's Farm (2202 Bishop Estates ... public and is designed to raise awareness and funds ... HSS Round-Up is free. Ticket purchases will be required ...
(Date:10/30/2014)... California (PRWEB) October 30, 2014 REV'D ... bars are now available through a unique service called, ... site designed to empower the everyday athlete. The Feed ... best athletes and created a system to pass that ... to see REV’D® is now available on The Feed!” ...
Breaking Medicine News(10 mins):Health News:Hodgkinson Street Mepham Rebrands 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3
... dysfunctions- painful intercourse, sexual dissatisfaction and a multitude ... the patients and their doctors communicated better, most ... all women, as they go through menopause, will ... known as genital atrophy. ,This results in ...
... back with a vengeance. The killer disease of the past is ... partner in its destructive mission. Full-blown cases of AIDS coupled with ... in Africa alone. What is alarming is that the death rate ... no signs of the destruction slowing down. ,Health experts argue ...
... deaths due to asthma can be prevented if the ... disease. According to WHO, around 150 million people suffer ... due to the disease every year. Asthma is a ... characterized by sudden recurring attacks of labored breathing, chest ...
... that wound healing in depressed people is four times slower ... a place in the latest issue of the journal, “Psychosomatic ... on the rate of wound healing, according to the researchers. ... the immune system, which may keep a wound from healing ...
... injure the donor, it is now established without doubt that a ... person needing it. And the good news is that the donor ... his/her liver. ,Donation of a piece of the liver's right ... It is increasingly being performed in the West where the demand ...
... for the treatment of cancer has nearly,doubled during ... survey of pharmaceutical,companies.,Currently, 170 pharmaceutical and biotechnology firms ... treatment of various,cancers, up from 215 in 1995. ... and chemotherapy. For lung cancer, the leading cause ...
Cached Medicine News:
... patented HEp-2 cell line that has been ... SS-A/Ro autoantibodies, without affecting the other ANA ... published worldwide on the HEp-2000 ANA substrate, ... when used in place of standard HEp-2 ...
... ANA and ENA assays can be ... for antinuclear antibodies, which are associated ... as Systemic lupus erythematosus (Lupus), Sjgren's ... systemic sclerosis, scleroderma, polymyositis, dermatomyositis, and ...
... ANA and ENA assays can be ... for antinuclear antibodies, which are associated ... as Systemic lupus erythematosus (Lupus), Sjgren's ... systemic sclerosis, scleroderma, polymyositis, dermatomyositis, and ...
... and ENA assays can be used ... antinuclear antibodies, which are associated with ... Systemic lupus erythematosus (Lupus), Sjgren's syndrome, ... sclerosis, scleroderma, polymyositis, dermatomyositis, and Raynaud's ...
Medicine Products: